Testing nimotuzumab with standard treatment for leftover glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial adds the targeted drug nimotuzumab to a common treatment plan (radiation and temozolomide) for people with newly diagnosed glioblastoma that wasn't fully removed during surgery. It may help if your tumor has a specific protein called EGFR.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have just been diagnosed with glioblastoma and the tumor was only partly removed during surgery, leaving some visible on scans.
- Your tumor has a protein called EGFR (tested on a sample from your surgery).
- You are healthy enough to perform daily activities like walking and self-care (KPS score of 50 or higher).
- You have not had chemotherapy or radiation for this cancer before.
- You can start treatment within 2 to 6 weeks after your surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a special type of radiofrequency electromagnetic field treatment to standard chemotherapy and radiation therapy helps people with newly diagnosed glioblastoma. It is for patients who are planning to receive standard treatment and have had surgery to remove the tumor.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.